Crysvita Effective at Easing Children’s Pain and Aiding Life Quality, Trial Shows

Crysvita Effective at Easing Children’s Pain and Aiding Life Quality, Trial Shows

284378

Crysvita Effective at Easing Children’s Pain and Aiding Life Quality, Trial Shows

Switching from conventional therapy to Crysvita (burosumab) leads to clinically relevant reductions in pain and fatigue, and better quality of life, in children with X-linked hypophosphatemia (XLH) ages 5 to 12, according to data from a Phase 3 clinical trial. These findings in patient-reported outcomes add to previous results from this trial showing that the therapy significantly lessened the severity of bone-related symptoms and aided growth in pediatric patients, ages 1 to 12. Altogether, these data…

You must be logged in to read/download the full post.